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ABSTRACT Morphological switch is tightly coupled with the pathogenesis of many dimorphic fungal pathogens. Cryptococcus
neoformans, the major causative agent of cryptococcal meningitis, mostly presents as the yeast form but is capable of switching
to the hyphal form. The filamentous form has long been associated with attenuated virulence, yet the underlying mechanism
remains elusive. We previously identified the master regulator Znf2 that controls the yeast-to-hypha transition in Cryptococcus.
Activation of Znf2 promotes hyphal formation and abolishes fungal virulence in vivo. Here we demonstrated that the cryptococ-
cal strain overexpressing ZNF2 elicited strong and yet temporally confined proinflammatory responses in the early stage of infec-
tion. In contrast, exacerbated inflammation in mice infected with the wild-type (WT) strain showed that they were unable to
control the infection. Animals inoculated with this filamentous Cryptococcus strain had fewer pulmonary eosinophils and
CD11c CD11b cells than animals inoculated withWT yeast. Moreover, mice infected with this strain developed protective
Th1- or Th17-type T cell responses. These findings suggest that the virulence attenuation of the filamentous form is likely due to
its elicitation of protective host responses. The antivirulence effect of Znf2 was independent of two previously identified factors
downstream of Znf2. Interestingly, mucosal immunizations with high doses of ZNF2-overexpressing cells, either in the live or
heat-killed form, offered 100% protection to the host from a subsequent challenge with the otherwise lethal clinical strain H99.
Our results demonstrate that heat-resistant cellular components presented in cryptococcal cells with activated ZNF2 elicit pro-
tective host immune responses. These findings could facilitate future research on novel immunological therapies.
IMPORTANCE Cryptococcal meningitis is one of the leading causes of death among AIDS patients. This disease presents a severe
threat to public health. The current antifungal regimens are unsatisfactory in controlling or clearing the pathogen Cryptococcus
neoformans. Immunotherapies and/or vaccines could be a promising approach to prevent or manage this deadly disease. How-
ever, the lack of understanding of host-pathogen interactions during cryptococcal infection greatly hampers the development of
effective immunotherapies. In this study, we discovered that inoculation of cryptococcal cells with activated Znf2, a morphogen-
esis regulator and an antivirulence factor, could shift the host pathological Th2 responses to the protective Th1 or Th17 re-
sponses. Importantly, we discovered that vaccination with either the viable or heat-killed form of ZNF2-overexpressing cells pro-
tected animals from the otherwise lethal infection by the highly virulent clinical strain. Our study suggests that the fungal
cellular component(s) of the ZNF2-overexpressing strain may provide potential vaccine candidate(s) for controlling the fatal dis-
ease.
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Morphotype transition is critical in many aspects for fungalpathogens to cause disease. It could increase the fitness of
microbes in the physiological conditions of the host or their resis-
tance to antimicrobial host responses. Alterations in cell surface
molecules during morphogenesis, for example, could shape the
immune recognition of fungal pathogens (1–13). Cryptococcus
neoformans, although not considered a classic dimorphic fungus,
is able to switch from the yeast morphotype to the hyphal mor-
photype. Earlier studies indicated an inverse relationship between
filamentation and virulence (14–19). However, the mechanisms
controlling the phase transition and virulence in Cryptococcus
remain to be defined. Research on the dimorphism-associated
host-pathogen interactions in the classic dimorphic fungal
pathogens have provided a more comprehensive understand-
ing of the antifungal immune response and facilitated the de-
velopment of novel immunotherapy for various mycoses. For
instance, the morphotype-specific adhesin Bad1 of Blastomyces
dermatitidis blocks the activation of T cells (20), and the cor-
responding deletion mutant strain evokes a protective immune
response and serves as a live-attenuated fungal cell vaccine to
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protect the host from lethal infection by the wild-type strain
(21–26). The Candida albicans hypha-specific surface protein
Als3 mediates in vivo attachment and invasion (27), and an
anti-Candida vaccine designed based on Als3 is now in clinical
trials (28). Vaccination is an effective strategy to prevent infec-
tions from a plethora of microbial pathogens, particularly
those that frequently interact with us.
Humans are potentially exposed to Cryptococcus neoformans
from the environment via respiration starting in early childhood
(29). Once established in the lungs, the fungal cells may remain
latent for months or even decades (29–33). Upon activation of
cryptococcal infection due to impaired or suppressed host immu-
nity, this fungus often disseminates to the central nervous system
(30, 34), causing fatal cryptococcal meningitis (34–36). Crypto-
coccal meningitis is one of the leading causes of death among
immunocompromised individuals (37), and this pathogen also
infects people with no known immune defects (38–40).
Efficient clearance of Cryptococcus is dependent on Th1-
polarized cell-mediated immunity. The hallmark cytokine of Th1
responses, gamma interferon (IFN-), is associated with classical
activation of macrophages and is indispensable in protection
against Cryptococcus (41). In contrast, Th2 responses exacerbate
the disease and promote the secretion of interleukin 4 (IL-4), IL-5,
and IL-13, which are associatedwith alternative activation ofmac-
rophages, pulmonary eosinophilia, and IgE expression during
Cryptococcus infection (41–47). These nonprotective Th2 cell re-
sponses are mediated by interferon regulatory factor 4 (IRF4)-
dependentCD11bCD11c conventional dendritic cells in amu-
rine inhalation model of cryptococcosis (48). Given the
association between the filamentous morphotype and virulence
attenuation in Cryptococcus, we decided to focus on the impact of
Cryptococcus morphotype on the host responses.
We recently discovered that themorphogenesis regulator Znf2
determines hyphal development in Cryptococcus (49, 50). Activa-
tion ofZNF2 by a constitutive promoter of theGPD1 gene (PGPD1-
ZNF2) (the strain with PGPD1-ZNF2 [PGPD1-ZNF2 strain] or the
ZNF2-overexpressing strain) promotes hyphal formation both in
vitro and in vivo and abolishes the ability of the highly virulent
clinical and reference serotype A strain H99 to cause fatal disease
in animals (50). Given that drastically lowering theH99 inoculum
(10-fold or even 100-fold reduction) still causes fatal disease with
only slightly prolonged median survival time (51) and that this
PGPD1-ZNF2 strain grows normally in vitro under conditions that
are relevant to those in the host (host-relevant conditions), the
attenuation of cryptococcal virulence by the activation of Znf2 is
not likely due to a simple growth defect of the PGPD1-ZNF2 strain
in vivo. We hypothesize that the cryptococcal cells with activated
ZNF2 shape the host immune response, particularly cell-mediated
immunity, toward a host-protective type. In this case, ZNF2-
overexpressing strains may serve as vaccine agents to protect the
host from subsequent lethal infection. Our study examined these
hypotheses and further explored the contributions of two known
downstream factors of Znf2 to its powerful antivirulence effect.
Our results demonstrate that heat-resistant cellular components
presented in the hyphal mutant cells are likely responsible for
eliciting protective host immune responses.
RESULTS
The PGPD1-ZNF2 strain induced temporally strong inflamma-
tory responses during early stages of infection. We previously
reported that the PGPD1-ZNF2 strain did not cause any fatality in
the infected mice up to 60 days postinfection when we ended the
study (50). All themicewere healthy and active by the termination
point. Interestingly, we noticed that these mice experienced a sig-
nificant loss of body weight around 1 week postinfection and then
regained it after an additional 5 days (Fig. 1A). In contrast, animals
infected with the wild-type (WT) H99 strain experienced a grad-
ual decline in body weight (Fig. 1A) and eventually succumbed to
the infection. According to studies of pulmonary bacterial infec-
tions (52), we speculated that the temporary body weight loss
might reflect strong inflammatory responses occurring in the
host.
Therefore, we decided to examine the levels of pulmonary in-
flammation in these two groups of animals. We picked the exam-
ination time points of day 1, day 7 (when the animals had the
lowest body weight), and day 12 (when the animals had gained
back the bodyweight) postinfection. At day 7, we observed similar
levels of immune cell infiltration in the lungs ofmice infectedwith
either the PGPD1-ZNF2 strain or the WT strain (Fig. 1B and C).
This was surprising, given that the fungal burden in the group
infected with the PGPD1-ZNF2 strain was about 100-fold lower
than that of the group infected with the WT strain (see Fig. S1 in
the supplemental material). Therefore, animals infected with the
hyphal cells were more efficient in recruiting immune cells than
the animals infected with the wild-type strain (WT control
group). Interestingly, the PGPD1-ZNF2 strain-infected group
showed significantly lower levels of pulmonary CD45 leukocytes
than those of theWT control group on day 12 despite their similar
levels on day 7 (Fig. 1C), suggesting a divergence of inflammatory
progression. To test this hypothesis, we examined the dynamics of
total lung cytokines. On day 1, all cytokines were at very low con-
centrations. On day 7, animals infected with the PGPD1-ZNF2
strain presented much higher levels of the proinflammatory cyto-
kines tested (IL-1, IL-1, tumor necrosis factor alpha [TNF-],
and granulocyte colony-stimulating factor [G-CSF]) and the ma-
jority of the chemokines tested (CC chemokine ligand 3 [CCL3],
CCL4, and CCL5) than those infected with theWT strain (Fig. 1D
and E). Notably, the levels of proinflammatory cytokines and
chemokines in the PGPD1-ZNF2 strain-infected group decreased
drastically on day 12 compared to the PGPD1-ZNF2 strain-infected
mice on day 7. These observations indicate that the PGPD1-ZNF2
strain elicited strong, yet temporally confined, inflammatory re-
sponses.
Given that the PGPD1-ZNF2 strain did not show any apparent
defect in growth or stress tolerance in host-relevant conditions
(50), our observations suggest that mice infected with the PGPD1-
ZNF2 strain are able to restrict rapid fungal proliferation, proba-
bly by eliciting effective immune responses during the early stages
of infection.
Infection by the PGPD1-ZNF2 strain helps recruit distinct cell
subsets to the lungs. In order to define the pulmonary cellular
infiltrates in response to the PGPD1-ZNF2 strain infection in mice,
we performed flow cytometry with total lung cells on day 7 and
day 12 postinfection. We found no significant difference in the
total CD45 leukocytes or any other cell subset between the
groups infected with the wild-type strain and the PGPD1-ZNF2
strain on day 7 (Fig. 2A and 1C). On day 12, however, we observed
significant differences in several cell infiltrate subsets. First, mice
infected with the PGPD1-ZNF2 strain showed significantly fewer
eosinophils and F4/80macrophages than the mice infected with
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theWT strain (Fig. 2B), whichmight contribute to the lower levels
of total pulmonary CD45 leukocytes observed in this group at
this time point (Fig. 1C). Second, the PGPD1-ZNF2 strain-infected
group had a significant increase of CD11c positive, CD11b inter-
mediate (CD11c CD11bin) cells, while the WT strain-infected
group had an increase of CD11cCD11b cells (Fig. 2B). Pulmo-
nary eosinophilia, alternative activation of macrophages, and the
development of CD11cCD11b conventional dendritic cells are
linked to the pathogenic Th2 immune responses during crypto-
coccal infections (41, 44, 48). Although we did not examine the
FIG 1 The PGPD1-ZNF2 strain elicits strong but temporary inflammatory response. (A) Curves of body weight changes in animals infected with the wild-type
(WT) H99 strain or the PGPD1-ZNF2 strain (data shown are from one experiment with eight mice in each group). (B) H&E staining of the lungs of mice infected
with thewild-typeH99 strain or the PGPD1-ZNF2 strain (magnification of4). The small insets display images at a highermagnification (40).Many fungal cells
lodge at alveoli of lungs inwild-type strain-infected animals, whereas few cells of themutant strain can be observed.White bar, 200m;black bar, 8m. (C)Total
pulmonary CD45 leukocyte count on day 7 and day 12 postinfection. (D and E) Proinflammatory cytokines (D) and chemokines (E) recovered from the
supernatant of the homogenized lungs (n 4). Values that are significantly different from the value formice infectedwith theWT strain are indicated by asterisks
as follows: *, P 0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001.
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quality of the infiltratedmacrophages, the decrease of eosinophilia
and CD11b CD11c cells might be beneficial to the animals in
the PGPD1-ZNF2 strain-infected group. In addition to the differ-
ential recruitment of macrophages and myeloid cells, infection
with the PGPD1-ZNF2 strain induced higher recruitment of CD4
T cells on day 12 (Fig. 2B). These observations lead us to hypoth-
esize that the quality of cell-mediated immunity upon infection
with the PGPD1-ZNF2 strain is skewed toward a protective re-
FIG 2 The PGPD1-ZNF2 strain elicits a distinct pattern of pulmonary cellular infiltration and T cell response. (A and B) Subsets of pulmonary cells on day 7 (A)
and day 12 (B) from the lungs ofmice infected with 105WTH99 strain or the PGPD1-ZNF2 strain (data shown are from three experiments using fourmice in each
group for each time point). (C) Th1, Th2, and Th17 response-related cytokines recovered from the supernatants of the homogenized lungs (four mice in each
group). *, P 0.05; **, P 0.01; ****, P 0.0001.
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sponse. This is in contrast to the infection with the parental H99
strain that appears to induce a response incapable of protecting
the host (Fig. 1).
We then examined the levels of cytokines involved in the
cell-mediated immune response. We observed that animals in-
fected with the PGPD1-ZNF2 strain showed a significant in-
crease in the levels of IL-12p40 and IL-12p70 on day 7, as well
as IFN- on day 12 (Fig. 2C), suggesting the development of
Th1-type cell-mediated immunity. In contrast, the levels of
major Th2 cytokines IL-4, IL-5, and IL-13 were significantly
increased in animals infected with the WT parental H99 strain
than in the animals infected with the PGPD1-ZNF2 strain. There
was also a trend of increased IL-17A production on day 12 (P
0.063) and significantly higher levels of Th17-related cytokines
(IL-6 and CXC chemokine ligand 1 [CXCL1]) in the PGPD1-
ZNF2 strain-infected group. The Th17 response was previously
found to be not critical but supportive for the defense against
cryptococcal infections (53, 54). Collectively, the results of
analyses of the infected lungs indicate that the PGPD1-ZNF2
strain likely altered the polarization of cell-mediated immune
response during infection toward the Th1 or Th17 (Th1/Th17)
type while suppressing the Th2 type.
The PGPD1-ZNF2 strain induces protective cell-mediated im-
munity.To examine whether the encounter with the PGPD1-ZNF2
Cryptococcus cells steered the host to differentiate protective T
helper cells, we collected cells from bronchoalveolar lavage fluid
(BALF) samples of animals infected with the wild-type H99 strain
or the PGPD1-ZNF2 strain on day 7 postinfection. The polarization
of CD4 T cells toward Th1, Th17, and Th2 responses was exam-
ined by the intracellular staining for the signature IFN-, IL-17A,
and IL-13 cytokines, respectively. Strikingly, CD4 T cells recov-
ered from the airways of the mice infected with the PGPD1-ZNF2
strain produced significantly higher levels of IFN- and IL-17A
(Fig. 3A to C) than CD4 T cells recovered from mice infected
with the WT strain. The phenotype was consistent with the anal-
ysis of global cytokine levels in lung tissue (Fig. 2C). These data
FIG 3 The PGPD1-ZNF2 strain alters the polarization of cell-mediated immunity. (A) CD4 T cell gate, intracellular staining of IFN- and IL-17A of uninfected
mice and mice infected with the WT or PGPD1-ZNF2 strain. (B to D) Frequencies of cells positive for IFN- (B), IL-17A (C), and IL-13 (D) out of total CD4 T
cells (n 7). (E) IFN-/IL-13 ratio of CD4 T cells. In panels B to E, each symbol represents the value for an individual mouse, and the short horizontal line
represents the mean value for the group of mice. (F) ELISA of IFN-, IL-17A, and IL-13 levels from purified mediastinal lymph node CD4 T cells restimulated
with Cryptococcus antigens (Ag) (data shown are from one experiment using seven mice in each group). *, P 0.05; **, P 0.01; ***, P 0.001; ****, P
0.0001.
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suggest that infection with the PGPD1-ZNF2 strain enhanced the
differentiation of beneficial Th1 and Th17 cells. Although the fre-
quencies of IL-13-producing CD4 T cells were similar in both
groups of infected mice (Fig. 3D), the IFN-/IL-13 ratio was sig-
nificantly higher in the PGPD1-ZNF2 strain-infected group
(Fig. 3E). Therefore, these findings indicate that the activation of
ZNF2 in Cryptococcus promotes a host response dominated by
protective Th1 cells.
To further examine the possible differential activation of
Cryptococcus-specific CD4 T cells in the two groups of infected
mice, we examined CD4 T cell responses in the lung-draining
mediastinal lymph node (MLN) on day 7 postinfection. Purified
MLN CD4 T cells were restimulated by co-culture with naive T
cell-depleted splenocytes in the presence or absence of cryptococ-
cal antigens. The response of Cryptococcus-specific CD4 T cells
was examined by measuring cytokine secretion in the culture su-
pernatants in an enzyme-linked immunosorbent assay (ELISA).
We included cocultures of purified CD4 T cells with splenocytes
without Cryptococcus antigen as controls for the specificity of the
response. As expected, cytokines were minimally produced with-
out the addition ofCryptococcus antigens (Fig. 3F). In the presence
ofCryptococcus antigens, however, the CD4 T cells isolated from
the PGPD1-ZNF2 strain-infected mice produced significantly
higher levels of IFN- and IL-17A and significantly lower levels of
IL-13 than the CD4 T cells isolated from WT strain-infected
mice (Fig. 3F). Taken together, these results strongly support the
hypothesis that the PGPD1-ZNF2 cryptococcal strain directs the
host cell-mediated immune response toward the protective Th1/
Th17 type.
Vaccination with live PGPD1-ZNF2 cells protects the host
from a subsequent challenge by the otherwise lethal wild-type
strain. The aforementioned evidence indicates that the immune
response that developed in mice infected with the PGPD1-ZNF2
strain could potentially be protective against a subsequent chal-
lenge by WT cryptococcal cells. This prompted us to examine
whether this strain could serve as a live-attenuated cryptococcal
cell vaccine to protect the host against a subsequent lethal infec-
tion. First, we performed a pilot study and tested two different
inoculation dosages of the live PGPD1-ZNF2 cells (1 103 and 1
104 CFU per animal). We found that the PGPD1-ZNF2 strain was
partially protective and that the protection was dose dependent
(see Fig. S2 in the supplementalmaterial). The animals challenged
on day 25 postimmunization exhibited a better level of protection
than those challenged on day 48 postimmunization (Fig. S2). We
also performed a coinfection experiment where mice were inocu-
lated with the PGPD1-ZNF2 and WT cells mixed at a 9:1 ratio. We
did not observe any protection compared with the infection with
WT cells alone. This suggests that the protective effect could be
achieved only sequentially, as observed for most vaccines cur-
rently in clinical use. On the basis of these results, we tested higher
doses of the PGPD1-ZNF2 strain (1  104, 1  105, and 1 
106CFUpermouse) for the vaccination and challenged thesemice
together with the nonvaccinated control mice with wild-type
strain H99 (1  104 cells per animal) on day 25 postvaccination
(Fig. 4A). As expected, all the mice in the unimmunized control
group died within 4 weeks after the challenge (Fig. 4B). Strikingly,
80%, 90%, and 100% of the mice immunized with the PGPD1-
ZNF2 strain at a dose of 1  104, 1  105, and 1  106 CFU,
respectively, survived without any moribund symptoms by
60 days postinfection with WT cells when we terminated the ex-
periment (Fig. 4B). Thus, the PGPD1-ZNF2 strain provided dose-
dependent protection to the host against otherwise lethal chal-
lenges with WT cells.
We further examined the fungal burden in lungs and brains of
the protected immunizedmice at the endpoint of the experiment.
We did not detect any cryptococcal cells in the brains of the ma-
jority of mice that survived the WT cryptococcal challenge for
60 days (Fig. 4D). The lungs of animals immunized with the
higher dose of the PGPD1-ZNF2 cells contained lower fungal bur-
dens (Fig. 4C), consistent with the dose-dependent protection for
survival. We were able to recover some PGPD1-ZNF2 cells, though
at very low numbers, from several of the surviving animals at the
end point of the experiment. This finding indicated that inducing
a protective immune response did not require total clearance of
the live-attenuated cells. Taken together, the data demonstrate
that immunization with the PGPD1-ZNF2 strain protects animals
FIG 4 The PGPD1-ZNF2 strain serves as a live-attenuated fungal cell vaccine. (A) Strategy of vaccination. (B) Survival curves plotted against time upon challenge
withWTH99 (data shown are from two experimentswith 10mice in each group for the 104 and 105 groups and 7mice in the 106 group). (C andD) Fungal burden
in the lungs (C) and brains (D) from the animals that survived 60 days after challenge in each vaccination group.
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from the subsequent lethal infection and restrains proliferation of
WTH99 cells in the lung. Such an effective immunization even led
to the clearance of the highly virulent H99 cells from several mice
in the experiment.
The antivirulence effect of Znf2 remains in the absence of
two Znf2 downstream factors. As the master regulator of mor-
phogenesis, Znf2 controls the expression of multiple factors (49,
50, 55). It is possible that some of its downstream factors account
for its antivirulence property. Two factors, Pum1 andCfl1, are the
major downstream factors contributing to the ZNF2-controlled
filamentation in vitro in the serotypeDXL280 background (50, 55,
56). Deletion of the CFL1 or PUM1 gene alone leads to less robust
hyphal growth in strain XL280. Disruption of both genes severely
reduces the hyphal formation in vitro, even when Znf2 is activated
(55). Given that serotype A isolates represent the vast majority of
Cryptococcus clinical isolates, we decided to investigate the contri-
butions of Pum1 and Cfl1 to the antivirulence effect of Znf2 in a
serotype A background.
We deleted both CFL1 and PUM1 genes in the PGPD1-ZNF2
strain in the H99 background. As expected, the robustness of hy-
phal formation was significantly reduced in the absence of CFL1
and PUM1 in vitro (Fig. 5A, top panels), consistent with our pre-
vious observations of the serotype D background (55). However,
we noticed that the degree of reduction in filamentation in vitro of
this PGPD1-ZNF2 cfl1 pum1 strain in the H99 background was
not as dramatic as we previously observed for the serotypeDback-
ground (55). We then tested the virulence and looked at the mor-
phology of this mutant strain in vivo in a murine model of cryp-
tococcosis. Grocott’s methenamine silver (GMS) staining of the
infected lung tissues indicated that the PGPD1-ZNF2 cfl1 pum1
strain displayed a mixed morphology in vivo (Fig. 5A, bottom
panels). All mice infected with this PGPD1-ZNF2 cfl1 pum1mu-
tant strain survived and appeared healthy whenwe terminated the
experiment 60 days postinfection (Fig. 5B). This was similar to
what we observed for the PGPD1-ZNF2 strain. In contrast, animals
infected with the same inoculum of wild-type H99 strain died
within 23 days postinfection (Fig. 5B). Consistent with the sur-
vival data, our histological examination of the lung tissues sug-
gested that the PGPD1-ZNF2 cfl1 pum1 strain elicited strong
inflammation in the lungs (Fig. 5C), which again resembled the
phenotype of lung infection by the PGPD1-ZNF2 strain.
We further examined the fungal burden in lungs and brains at
10 days postinfection. The mice infected with the PGPD1-ZNF2
cfl1 pum1 strain had lung fungal burdens about 3 orders of
magnitude lower than those in the H99-infected animals
(Fig. 5D). Furthermore, no fungal cells were recovered from the
brains of animals infected with themutant strain (Fig. 5D). All the
in vivo phenotypes observed for the PGPD1-ZNF2 cfl1 pum1
strain resembled what we previously observed for the parental
PGPD1-ZNF2 strain (50). The results indicate that Cfl1 and Pum1
do not contribute to the antivirulence effect of Znf2.
Cellular components of ZNF2-overexpressing strains pro-
vide vaccination effect to the host.Twohypotheses could explain
the antivirulence effect of Znf2. First, the active metabolism of
FIG 5 Two downstream targets of Znf2, CFL1 and PUM1, do not contribute to Znf2’s antivirulence effect. (A) Morphology of the PGPD1-ZNF2 strain and the
PGPD1-ZNF2 cfl1 pum1 strain in vitro (24 h of incubation in DMEM plus 10% FBS at 37°C under 5%CO2) and in vivo (GMS staining of lung tissues from the
infected mice). Bar, 10m. (B) Survival curves of the PGPD1-ZNF2 cfl1 pum1 strain and wild-type H99 strain (the results for one experiment are shown, with
eight mice in each group). (C) H&E staining of the lung tissues. Pseudohyphal cells were enveloped by the well-developed bronchus-associated lymphoid tissue
(black arrow). Bar, 100 m. (D) Lung and brain fungal burden of animals infected with the PGPD1-ZNF2 cfl1 pum1 strain and wild-type H99 strain (one
experiment, with four mice in each group). N.D., not detected.
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cryptococcal cells transitioning from the yeast form to the hyphal
form may be directly associated with the virulence attenuation
and vaccination effect observed earlier (Fig. 4). Alternatively, cell
components that are prominently presented in ZNF2-
overexpressing strains may serve as potent antigens to elicit a
strong protective host response. The first hypothesis would re-
quire the presence of viable ZNF2-overexpressing cells for protec-
tion. Given that we were able to recover low levels of fungal cells
from seven out of eight lungs from mice infected with the PGPD1-
ZNF2 strain on day 60 postinoculation (see Fig. S3 in the supple-
mental material), it was reasonable to speculate that most of the
immunized mice still had viable PGPD1-ZNF2 cells at the time of
challenge by the WT strain on day 25 or day 48 after inoculation
with the PGPD1-ZNF2 strain.
The second hypothesis, however, would predict that it was the
alteration in cellular components enacted by Znf2 (e.g., cell sur-
face remodeling) that provided potent antigens to elicit a strong
protective host response. In such a scenario, a component(s) from
the ZNF2-overexpressing cells could exert a similar effect on the
host regardless of whether the strain remained viable or whether it
retained the ability to proliferate.
Previous studies have demonstrated that the heat-killed wild-
type strain could not provide protection (57, 58). Our pilot exper-
iment showed that one-time inoculation with the heat-killed
PGPD1-ZNF2 strain at a dose of 1  104 or 1  105 CFU/animal
offered no protection (see Fig. S4 in the supplemental material).
Given that the live PGPD1-ZNF2 strain provided dose-dependent
protection (Fig. 4), we decided to examine the protective effect of
heat-killed ZNF2-overexpressing strains with higher doses (106 or
107). For this purpose, we chose to employ two strains with differ-
ent promoters driving the expression ofZNF2. Onewas the PGPD1-
ZNF2 strain used in this study and the previous study (50). The
PGPD1-ZNF2 strain had constitutively active expression of
ZNF2, and the level of its expression was modestly high (50).
Consequently, this strain displayed mixed morphotypes (yeast,
pseudohyphae, and hyphae) under both in vitro growth condi-
tions and in animal lungs during infection (50). The second
strain was the PCTR4-2-ZNF2 strain, where the inducible pro-
moter of the copper transporter CTR4 drove the expression of
ZNF2. The expression of ZNF2 could be induced to such a high
level by copper limitation that the whole population could turn
filamentous (55) (Fig. 6B). The live PCTR4-2-ZNF2 cells were
not used earlier to study the effect of Znf2 on virulence because
of the necessity of manipulating copper levels in the host. How-
ever, for the purpose of using heat-inactivated cells in this ex-
periment, the manipulation of copper levels in the host was not
required. We included heat-killed wild-type H99 cells at a vac-
cination dose of 1  107 as a control.
To achieve a better protection effect using inviable cells, we
decided to modify the vaccination strategy. Here we vaccinated
the animals with two doses of heat-killed cells, one at day32 and
one at day 7 (day 0 was the day the mice were challenged with
lethal clinical strain H99). Then, we challenged the immunized
mice with live WT H99 (1  104 cells/animal) 7 days after the
booster dose (Fig. 6C). Excitingly, both heat-killed ZNF2-
overexpressing strains protected the mice from the otherwise le-
thal challenge, while the heat-killed WT cells did not offer any
protection (Fig. 6C). This finding suggests that changes in cell
components caused by the activation of ZNF2, rather than the
persistence of the mutant cells in vivo, were responsible for the
protective effect. We terminated the experiment at day 60 post-
challenge and evaluated the organ fungal burden. The wild-type
H99 cells were cleared from more than half of the immunized
animals during the period of this experiment, suggesting that the
immunization could help animals clear or restrict cryptococcal
proliferation in the lungs (Fig. 6D).More importantly, none of the
animals had any brain infection at the termination point of this
experiment. Taken together, our studies suggest that heat-
FIG 6 Heat-killed cells of two different ZNF2-overexpressing strains offer protection to the host. (A) Strategy of vaccination. (B) Cellular morphology of the
PGPD1-ZNF2 strain and the PCTR4-2-ZNF2 strain. Bar, 5m. (C) Survival curves of mice vaccinated by heat-killed (HK) cells of strain H99 (n 10), PGPD1-ZNF2
(n 4), or PCTR4-2-ZNF2 (n 4). (E) Fungal burden in the lungs of immunized animals at the end of the experiment (60 days postchallenge).
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resistant fungal components from two hyphal mutant strains
could offer promising protection from the otherwise lethal cryp-
tococcal infections.
DISCUSSION
Morphological switch is tightly linked to pathogenesis in many
pathogenic fungi. In Cryptococcus, Znf2 provides the underlying
molecular link between morphology and pathogenesis. However,
how Znf2 impacts cryptococcal pathogenesis and whether its an-
tivirulence effect could be useful for translational studies remain
unknown.
The activation of Znf2 abolishes cryptococcal virulence, but it
does not reduce cryptococcal fitness or stress tolerance. This dif-
fers from many other mutations that attenuate fungal virulence.
Interestingly, during the survival study, we observed one episode
of relapse in one mouse infected with the live PGPD1-ZNF2 strain.
This animal lost about one-third of its body weight within a week
at aroundweek 4 postinfection, but it gradually recovered its orig-
inal body weight after another 2 weeks. Except for the weight loss,
this animal did not show any moribund symptoms during the
time course of the experiment. Nonetheless, it showed a relatively
high lung fungal burden (~106 CFU) and brain dissemination
when we terminated the experiment (see Fig. S3 [asterisks] in the
supplemental material). The observation of relapse reinforced the
notion that the PGPD1-ZNF2 strain can proliferate in vivo and that
it possesses the ability to disseminate to the central nervous system
(CNS). Therefore, we believe that the protective host response
elicited by the PGPD1-ZNF2 cells, rather than any growth defect of
the PGPD1-ZNF2 strains in vivo, is mainly responsible for the con-
tainment of the infection.
It is important to note that the host response elicited by the
PGPD1-ZNF2 cells is stage dependent, which is critical for protec-
tion. For instance, at day 7, the infection led to an influx of CD45
leukocytes to the primary infectious site and dramatically en-
hanced the secretion ofmajor proinflammatory cytokines.During
the second week of infection, however, the level of inflammation
was reduced. The mitigation of host inflammatory responses is
essential to the protective effect, as strong and prolonged inflam-
mation is detrimental or even fatal: mutants (e.g., rim101 mu-
tants) that elicit exacerbated and persistent pulmonary inflamma-
tion could cause even earlier death in animals than the highly
virulent wild-type H99 strain does (59, 60).
We speculate that this rapid decrease of inflammation resulted
from effective antigen presentation. The flow cytometry data
showed a different pattern of CD11c cell subsets inmice infected
with the PGPD1-ZNF2 strain compared to theWT strain on day 12,
but not on day 7 (Fig. 2B). Mice infected with the PGPD1-ZNF2
strain presented significantly higher CD11c CD11bin cells and
lower levels of the pathological CD11c CD11b conventional
dendritic cells (DCs). Therefore, we propose that the increased
CD11c CD11bin cells are associated with a protective response.
Accordingly, the antigen-presenting cells (APCs) that interacted
with the PGPD1-ZNF2 cells directed a type 1 T helper cell differen-
tiation in the host (Fig. 3A). A thorough investigation into the
different APC subsets generated during the PGPD1-ZNF2 strain
infection will help us better understand the protective immune
response in the future.
Another exciting finding is that the ZNF2-overexpressing cells,
in the viable or heat-killed form, can protect the host from chal-
lenge with the lethal wild-type strain. To our knowledge, no
virulence-attenuated Cryptococcus strain reported so far provides
such a level of protection. The only exception is the viable form of
the H99 strain expressing the protective cytokine IFN- (H99):
the viable H99 can provide 100% protection to animals, yet the
heat-killed H99 fails (61–63). This current discovery suggests
that a fungal factor(s) controlled by Znf2 is capable of initiating
potent protective responses. Surprisingly, two factors contribut-
ing to the Znf2-mediated filamentation in vitro, Cfl1 and Pum1,
are not required for the antivirulence effect of Znf2. Animals in-
fected with the PGPD1-ZNF2 cfl1 pum1 strain survived through
the study, as we observed for the PGPD1-ZNF2 strain. One plausi-
ble explanation is that Cfl1 and Pum1 are present at levels too low
in the yeast form of Cryptococcus to serve as effective antigens that
elicit protective host responses against yeast infections. Therefore,
the major factors contributing to the antivirulence effect of Znf2
are yet to be identified. The successful protection offered by the
two different types of heat-killed ZNF2-overexpressing cells sug-
gests that characterization of the cellular component(s) of the
ZNF2-overexpressing cells is the key to pinpoint the cryptococcal
factors that elicit host protective immune responses. Additionally,
it would be interesting to compare the type of T cell response
induced by the live mutant cells with that induced by heat-killed
cells and examine whether a similar Th1/Th17-type cell-mediated
immunity is present in both.
Altogether, our results unveiled the effect of Znf2 on host-
pathogen interactions during Cryptococcus infection. More im-
portantly, the protective effect of ZNF2-overexpressing cells pro-
vides a promising lead for future development of vaccination
agents against this fatal disease.
MATERIALS AND METHODS
Ethics statement. This study was performed according to the guidelines
of NIH and Institutional Animal Care andUse Committee (IACUC). The
animal models and procedures used have been approved by the IACUCs
at Texas A&M University (protocols 2011-22 and 2014-0049), Rutgers
University (12020D0615), and the University of Texas at San Antonio
(MU021).
Mutant generation and strain growth conditions. The Cryptococcus
strains used in the study are the wild-type H99 strain (64), the PGPD1-
ZNF2 strain (LW10) (50), the PCTR4-2-ZNF2 strain (LW30) (50), and the
PGPD1-ZNF2 cfl1 pum1 strain (generated for this study). AllCryptococ-
cus strainsweremaintained on yeast extract-peptone-dextrose (YPD)me-
dium at 30°C unless indicated otherwise. The ZNF2oe (oe stands for over-
expressing) cfl1 pum1 triple mutant strain is constructed by replacing
the CFL1 gene and the PUM1 gene with the hygromycin (HYG) and the
nourseothricin (NAT) drug cassette, respectively, in the PGPD1-ZNF2
strain (LW10) background. The construct generation and cryptococcal
biolistic transformation were performed essentially as we described pre-
viously (55). Primers used for making the knockout constructs are listed
in Table S1 in the supplemental material.
To culture the fungal strains for infection, fungal strains were
streaked out from 80°C freezer stock and inoculated on YPD agar
plates at 30°C for 2 days. Then, the fungal cells were inoculated in 2 to
3 ml YPD liquid medium at 30°C with shaking at 250 rpm overnight.
When grown under these conditions, PGPD1-ZNF2 and PGPD1-ZNF2
cfl1 pum1 strains would form clumps. In order to obtain single-cell
suspensions, overnight liquid cultures were allowed to sit on a bench
for 15 to 20 min to let the large clumpy cells precipitate. The upper
layer of the liquid culture was collected and centrifuged at 3,000 rpm
for 2 min, and the cell pellets were used for the following washing and
counting steps. In this case, more than 95% of the collected cells would
be yeast or small butterfly-shaped cells. The actual inoculation should
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be verified by plating the cell suspension on YPD agar plates and
counting the number of CFU after incubation.
Murinemodel of cryptococcosis.FemaleA/Jmice of 8 to 10weeks old
were purchased from the Jackson Laboratory (Bar Harbor, ME). In sur-
vival assays, 8 to 10 mice were assigned to each group. To prepare fungal
cells for infection, strains were cultured in RPMI 1640medium overnight
at 37°C with shaking at 250 rpm to reduce cell aggregation. The fungal
cells were washed with sterile 0.9% saline three times, and the final con-
centration of the cell suspension was adjusted with saline to 2 106 cell/
ml. Mice were sedated with ketamine and xylazine via intraperitoneal
injection and then inoculated intranasally with 50 l fungal cell suspen-
sion as previously described (51, 65). After infection, animals were
weighed daily and monitored twice a day for progression of disease, in-
cluding weight loss, gait changes, labored breathing, or fur ruffling. Mor-
ibundmice were sacrificed. The change of bodyweight of each animal was
calculated as follows: [(weight on day Xweight on day 2)/weight on day
2] 100%. The resulting data on body weight change were then plotted
against time.
Cytokine analysis.The lungs of infected animalswere dissected on the
indicated days (indicated on the figures) and homogenized in 1 ml ice-
cold antiprotease buffer solution containing phosphate-buffered saline
(PBS), protease inhibitors (inhibiting cysteine, serine, and other metallo-
proteinases), and 0.05% Triton X-100. The mixtures were centrifuged at
800 g for 5min at 4°C. The supernatant of each sample was collected for
cytokine analysis using the Bio-Plex protein array system (Luminex-based
technology; Bio-Rad Laboratories, Hercules, CA) according to the in-
structions provided by the manufacturer (66).
Histology assays. The animals infected with different Cryptococcus
strains were sacrificed on the indicated days (indicated on the figures),
and their lungs and brains were harvested. The organs were fixed in 10%
formalin, embedded in paraffin, sliced into 5-m-thick sections, and pro-
cessed either with hematoxylin-and-eosin (H&E) staining for bronchus-
associated lymphoid tissue, or with Grocott’s methenamine silver (GMS)
staining for the fungal morphology observation in vivo.
Organ fungal burden analysis.The infection procedure is the same as
in the survival study. At the time of sacrifice, the lungs and brains were
dissected. The dissected organs were homogenized in 2ml cold PBS buffer
with the same setting for each type of organ. The tissue suspensions were
serially diluted (10 times), plated onto YNB agar medium, and incubated
at 30°C for 2 days such that the colonies became visible so that the number
of CFUs could be counted.
Pulmonary leukocyte isolation. Lungs were excised at the indicated
time points (indicated in the figures) and digested enzymatically at 37°C
for 30min in 10ml of digestion buffer (RPMI 1640medium and 1mg/ml
of collagenase type IV [Sigma-Aldrich, St. Louis, MO]) with intermittent
(every 10 min) stomacher homogenizations. The enzymatically digested
tissues were then successively filtered through sterile nylon filters of vari-
ous pore sizes (70 and 40 m) (BD Biosciences) and washed with sterile
Hanks balanced salt solution (HBSS) to enrich for leukocytes. Erythro-
cytes were lysed by incubation in NH4Cl buffer (0.859% NH4Cl, 0.1%
KHCO3, 0.0372% Na2EDTA [pH 7.4]; Sigma-Aldrich) for 3 min on ice
followed by the addition of a 10-fold excess of PBS. The resulting leuko-
cyte population was then collected by centrifugation (800 g) for 5 min,
washed twice with sterile PBS, resuspended in sterile PBS plus 2% heat-
inactivated fetal bovine serum (FBS) (fluorescence-activated cell sorting
[FACS] buffer) and enumerated in a hemacytometer using trypan blue
dye exclusion. Flow cytometric analysis was used to determine the per-
centage of each leukocyte population as well as the absolute number of
total leukocytes (CD45) within the lung cell suspension for standardiza-
tion of hemacytometer counts.
Total lung cell surface staining and flow cytometry. Standard meth-
odology was employed for the direct immunofluorescence of pulmonary
leukocytes. Briefly, in 96-well U-bottom plates, 100l containing 1 106
cells in PBS plus 2% FBS (FACS buffer) were incubated with 50 l of Fc
Block (BD Biosciences) diluted in FACS buffer for 5 min to block non-
specific binding of antibodies to cellular Fc receptors. Subsequently, an
optimal concentration of fluorochrome-conjugated antibodies (eBiosci-
ence [SanDiego, CA] andMolecular Probes [Eugene, OR]) (between 0.06
and 0.5 g/1  106 cells in 50 l of FACS buffer) were added in various
combinations to allow for dual or triple staining experiments, and plates
were incubated at 4°C for 30 min. Following incubation, the cells were
washed three times with FACS buffer, and cells were fixed in 200l of 2%
ultrapure formaldehyde (Polysciences, Inc., Warrington, PA) diluted in
FACS buffer (fixation buffer). Cells incubated with either FACS buffer
alone or single-fluorochrome-conjugated antibodies were used to deter-
mine positive staining and spillover/compensation calculations, and the
flow cytometer determined the background fluorescence. The samples
were analyzed using a BD FACSArray flow cytometer (BD Biosciences),
and FlowJo was used to determine cell populations. Dead cells were ex-
cluded on the basis of forward angle and 90° light scatter. For data analy-
ses, 30,000 events (cells) were evaluated from a predominantly leukocytic
population identified by back-gating from stained CD45 cells. The ab-
solute number of total leukocytes was quantified by multiplying the total
number of cells observed by hemacytometer counting by the average per-
centage of CD45 cells determined by flow cytometry. The absolute num-
ber of each leukocyte subset (Ly6G, F4/80MHCII [MHCII stands for
major histocompatibility complex class II], CD11c CD11bin, CD11c
CD11b, CD19, Siglec-F CD11bin, CD4 CD3, and CD8 CD3)
was determined by multiplying the percentage of each gated population
by the total number of CD45 cells.
BALF cell stimulation and intracellular staining. Bronchoalveolar
lavage fluid (BALF) samples were harvested 7 days after inoculation, and
cells were plated in a round-bottom 96-well plate where they were reacti-
vated with a leukocyte activation cocktail with GolgiPlug (BD Pharmin-
gen) in RPMI 1640 medium containing 10% fetal calf serum (FCS) and
penicillin-streptomycin (PenStrep). The cells were then washed and
stained for cell surface markers and fixed in 1% paraformaldehyde (PFA)
overnight. Then, cells were permeabilized for intracellular staining and
analyzed in a BD LSR II flow cytometer.
CD4 T cell restimulation frommediastinal lymph nodes.Medias-
tinal lymph nodes were harvested 7 days after inoculation, and cells from
the same group were pooled and used for CD4 T cell enrichment by a
negative-sorting CD4 isolation kit (Miltenyi Biotec). Then, 2 105 iso-
lated CD4 T cells were cocultured with 3 105 T cell-depleted spleno-
cytes, with the addition of voriconazole (final concentration of 1.25 g/
ml) or live H99 cells as a source of Cryptococcus antigen in RPMI 1640
medium containing 10% FCS and PenStrep. The culture was maintained
for 3 days, and the supernatant was harvested to measure cytokine pro-
duction according to the manufacturer’s instructions for the Ready-SET-
Go! (eBioscience) enzyme-linked immunosorbent assay (ELISA) kits.
T cell-depleted splenocytes were generated by obtaining a single-cell
suspension of a naive spleen and treated with red blood cell (RBC) lysis
buffer to remove red blood cells. After the cells were washed with PBS,
splenocytes were incubated at 37°C in 5 ml of RPMI 1640 medium (10%
FCS and PenStrep) containing anti-Thy1.2 antibody and Low-ToxM rab-
bit complement (Cedarlane) to remove T cells. Finally, the cells were
washed and counted.
Vaccination. For the live-cell vaccination,mice were vaccinated intra-
nasally with different doses (104, 105, and 106) of the live PGPD1-ZNF2
cells. The concentration of fungal cell in suspension was adjusted accord-
ing to the required inocula to meet the volume requirement of 50 l per
inoculation. The vaccinated groups and the naive group (negative con-
trol) were challenged with 1  104 wild-type H99 cells 25 or 48 days
postvaccination. For the heat-killed cell vaccination, H99 and PGPD1-
ZNF2 cells were cultured in YPD liquid medium at 30°C with shaking
(250 rpm) overnight. The PCTR4-2-ZNF2 cells were cultured in YPD liquid
medium plus 200 M copper chelator bathocuproine disulfonate (BCS)
at 30°C overnight without shaking. Cells of the three fungal strains were
precipitated at 3,000 rpm for 2min andwashed twicewith sterile PBS. The
concentration of fungal cell suspension was adjusted according to the
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required inocula to meet the volume requirement of 50 l per inocula-
tion. The cell suspension with the correct concentration was then ali-
quoted into 1.7-ml tubes and heated in a boiling water bath for 20 min.
The viability of the cells after such treatment was examined by plating the
processed cell suspension on YPD agar plate; no colonies were recovered
after incubating at 30°C for 3 days.Mice were vaccinated intranasally with
the heat-killed fungal strains at day32.Mice were vaccinated again with
the same dose of heat-killed fungal strains at day7. All the animals were
challenged with 104 live H99 cells via intranasal inoculation 32 days after
the first vaccination. Animals after the live H99 cell challenge were
weighed andmonitored daily for disease progression, andmoribundmice
were sacrificed. All the animals were terminated on day 60 after challenge
with live H99.
Statistical analysis. Statistical significance of the survival data for the
different groups was assessed by the Gehan-Breslow Wilcoxon test. Mul-
tiple t tests were applied in the grouped cytokine profiling/cell infiltration
data. The intracellular staining data were analyzed by nonparametric
Mann-Whitney test. All statistical analyses were performed using the
GraphPad Prism 6 program, with P values lower than 0.05 considered
statistically significant.
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